Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR) - Tanaka, Atsushi; Shibata, Hirotaka; Imai, Takumi; Yoshida, Hisako; Miyazono, Motoaki; Takahashi, Naohiko; Fukuda, Daiju; Okada, Yosuke; Teragawa, Hiroki; Suwa, Satoru; Kida, Keisuke; Moroi, Masao; et al. (Cardiovascular diabetology, 2023)
Keywords: Ankle; Biomarker; Biomarkers; Blood pressure; Chronic kidney disease; Clinical trials; Consent; Creatinine; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - drug therapy; Double-Blind Method; Double-blind studies; Drug dosages; Drug therapy; Ejection fraction; Epidermal growth factor receptors; Finerenone; Humans; Inflammation; Kidney diseases; Mineralocorticoid receptors; Mortality; Patients; Placebos; Potassium; Prospective Studies; Proteomics; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - diagnosis; Renal Insufficiency, Chronic - drug therapy; Study Protocol; Type 2 diabetes; Vascular Stiffness; Japan; Type 2 diabetes; Biomarker; Chronic kidney disease; Finerenone; Vascular stiffness